Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Paraganglioma × lanreotide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 8 Carcinoid Tumor 3 Acromegaly 3 Pituitary Neoplasms 2 Carcinoma, Hepatocellular 2 Pheochromocytoma 1 Paraganglioma 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Neoplasm Metastasis 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Carcinoma, Merkel Cell 1

Interventions

lutetium Lu 177 dotatate 4 3-Iodobenzylguanidine 3 gallium Ga 68 dotatate 2 anlotinib 2 Phenoxybenzamine 2 Magnetic Resonance Spectroscopy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 olaparib 1 lanreotide 1 fluorodopa F 18 1 fludarabine phosphate 1 cabozantinib 1 belzutifan 1 atezolizumab 1 Vorinostat 1 Temozolomide 1 Sunitinib 1 Specimen Handling 1 Radiosurgery 1 Interleukin-13 1 Genetic Testing 1 Fluorodeoxyglucose F18 1 Doxazosin 1 Cyclophosphamide 1 Blood Specimen Collection 1 Biopsy 1 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 1 3-fluorobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡